The document included in this post was sent to me by an anonymous source. It’s a technical and somewhat difficult read, but valuable information nonetheless.
It’s pretty evident that for a lengthy period, many interested parties have been trying to manipulate coronaviruses for the purpose of harming the public or for profiting monetarily. Visitors here can read the document below and see just how deep the rabbit hole goes.
I have written prior that scientists working for public and private sources have undoubtedly attempted to genetically manipulate these viral structures for nefarious purposes. Great amounts of funding have gone into these attempts to create and secure bioweapons against humanity.
In my considered opinion, the efforts to reach the above-referenced objective have fallen short. Because viral pathogens are too unpredictable and difficult to stabilize in lethal forms, it ultimately became easier for the controlling powers to fake a world pandemic than create one in real life.
— Dr. Reizer
Click on the image below to read the full PDF document:
David E. Martin, Ph.D.
Dr. David Martin is the founding CEO of M∙CAM Inc. M∙CAM is the international leader in intellectual property-based financial risk management. From auditing patent quality for governments and patent offices to providing state-of-the-art actuarial risk management systems and solutions to the largest banks and insurance companies, M∙CAM has established a global standard in patent quality and commercial validity assessment and management.
A spokesperson for global intellectual property accountability and quality reform, Dr. Martin has worked closely with the United States Congress, numerous trade and financial regulatory agencies in the United States, Europe, and Asia, in advocating and deploying infrastructure to support growing reliance on proprietary rights in business transactions. M∙CAM has supported the modernization of intellectual property, tax, and accounting laws through its work with oversight agencies and policymakers.
Dr. Martin has founded several for-profit and non-profit companies and organizations and serves on several boards. He was the founding CEO of Mosaic Technologies Inc., a company that developed and commercialized advanced computational linguistics technologies, dynamic data compression and encryption technologies, electrical field transmission technology, medical diagnostics, and stealth/anechoic technology. He was a founding member of Japan’s Institute for Interface Science & Technology. He founded and served as Executive Director of the Charlottesville Venture Group. He has served as a board member for the Research Institute for Small and Emerging Business (Washington D.C.), the Academy for Augmenting Grassroots Technological Innovations (India), the IST (Japan) the Charlottesville Regional Chamber of Commerce (Virginia), and the Charlottesville Industrial Development Agency (Virginia).
As a former Assistant Professor at the University of Virginia’s School of Medicine, Dr. Martin founded the University’s first wholly-owned, for-profit, research and development and technology transfer corporation. Engaged in domestic and international technology transfer, clinical research, and financing, this company pioneered new techniques of innovation management that have become industry standards. In 1999, Dr. Martin was appointed by the Governor of the Commonwealth of Virginia to serve on the Joint Commission on Technology and Science and has served the General Assembly and Virginia’s Center for Innovative Technology on numerous occasions.
Dr. Martin’s work with the Batten Institute at the Darden Graduate School of Business Administration at the University of Virginia and his related work at the Indian Institute for Management in Ahmedabad, India, has brought unprecedented curricular focus to areas of intangible asset risk management, finance, and accounting standards. In addition to his academic work, Dr. Martin has closely advised intellectual property-based finance and investment programs in India, China, Denmark, the European Union, the United Kingdom, South Africa, the Islamic Republic of Iran, the United States the United Arab Emirates.
Dr. Martin has publications in law, medicine, engineering, finance, and education. He maintains active research in the fields of linguistic genomics, fractal financial risk modeling, as well as continuing his over 15 years of research in cellular membrane ionic signaling.
The Target List Movie is Coming to Amazon Prime This Summer
In association with River Rose Productions, Mad Wife Productions has announced that The Target List movie will begin filming on April 10, 2021.
Help Me Expose Big Pharma!
$4,500.00 Generously Donated So Far!
We are continuing our fundraising efforts for the movie. The movie production companies bringing this film to life have generously invested money into this project and have asked me to help them out by promoting a fundraiser to offset production expenses.
Next, screenshot your signed name on the petition platform, print a hardcopy, and keep it in a safe place.